BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 12, 2007
View Archived Issues
Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights
Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)
Read More
ImClone Gains On Erbitux Results; Avastin In Danger?
Read More
Enobia Gets $38M In Series B For Enzyme Replacement Trials
Read More
Nabi's 'Turnaround' Continues, Sells Biologics Unit For $185M
Read More
Aptuit Paying $64M For Evotec Chemistry Unit
Read More
Clinic Roundup
Read More
Other News To Note
Read More